Dragon, 1942

https://red.mnstate.edu/yearbooks/1026/thumbnail.jp

Additional file 3: of Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Figure S3. (A) The expression of apoptotic related genes Bcl-2, cyclin D1, c-FLIP, caspase 3, caspase 7 in H1299 cells when treated with bexarotene, bexarotene in combination with GW9662 respectively. (B) The expression of apoptotic related genes Bcl-2, cyclin D1, c-FLIP, caspase 3, caspase 7 in slc10a2 overexpressed H1299 cells when treated with bexarotene, bexarotene in combination with GW9662 respectively. (C) The expression of tumor suppressor genes PTEN, P21, P53, LKB1, TSC2 in H1299 cells when treated with bexarotene, bexarotene in combination with GW9662 respectively. (D) The expression of tumor suppressor genes PTEN, P21, P53, LKB1, TSC2 in slc10a2 overexpressed H1299 cells when treated with bexarotene, bexarotene in combination with GW9662 respectively. H1299 cells without any treatment as control group. All experiments were repeated 3 times. (TIFF 882 kb

Additional file 2: of Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Figure S2. (A) The expression of apoptotic related genes Bcl-2, cyclin D1, c-FLIP, caspase 3, caspase 7 in H1299 cells treated with bexarotene, overexpressed slc10a2 in combination with bexarotene, slc10a2-shRNA in combination with bexarotene respectively. (B) The expression of tumor suppressor genes PTEN, P21, P53, LKB1, TSC2 in H1299 cells treated with bexarotene, overexpressed slc10a2 in combination with bexarotene, slc10a2-shRNA in combination with bexarotene respectively, H1299 cells without any treatment as control group. All experiments were repeated 3 times. (TIFF 516 kb

Image_1_Breast-conserving surgery without axillary surgery and radiation versus mastectomy plus axillary dissection in elderly breast cancer patients: A retrospective study.jpeg

BackgroundThe high relative mortality rate in elderly breast cancer patients is most likely the result of comorbidities rather than the tumor load. Foregoing axillary lymph node dissection or omitting radiotherapy after breast-conserving surgery (BCS) does not affect the prognosis of elderly breast cancer patients. We sought to assess the safety of breast-conserving surgery without axillary lymph node dissection as well as breast and axillary radiotherapy (BCSNR) in elderly patients with early-stage breast cancer.MethodsWe retrospectively included 541 consecutive breast cancer patients aged over 70 years with clinically negative axillary lymph nodes in one clinical center. Of these patients, 181 underwent mastectomy plus axillary lymph node dissection (MALND) with negative axillary cleaning and 360 underwent BCSNR.ResultsAfter a median follow-up of 5 years, there was no significant difference between the BCSNR and MALND groups in either distant recurrence-free survival (DRFS) (p=0.990) or breast cancer-specific survival (p=0.076). Ipsilateral axillary disease was found in 11 (3.1%) patients in the BCSNR group and 3 (1.7%) patients in the MALND group; this difference was not significant (p=0.334). We did not observe a significant difference in distant recurrence between the groups (p=0.574), with 25 (6.9%) patients in the BCSNR group experiencing distant recurrence compared to 15 (8.3%) patients in the MALND group. Our findings did show a significant difference in ipsilateral breast cancer recurrence (IBTR), with 31 (8.6%) patients in the BCSNR group experiencing IBTR compared to only 2 (1.1%) patients in the MALND group (p=0.003).ConclusionBCSNR is a safe treatment option for elderly breast cancer patients with clinically negative axillary lymph nodes.</p

Flow chart for the selection of the included studies.

<p>Flow chart for the selection of the included studies.</p

Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis

<div><p>Background</p><p>The diagnostic performance of indocyanine green (ICG) fluorescence-guided sentinel lymph node biopsy (SLNB) for the presence of metastases in breast cancer remains unclear.</p><p>Objective</p><p>We performed a meta-analysis to investigate the diagnostic performance of ICG-guided SLNB.</p><p>Methods</p><p>Eligible studies were identified from searches of the databases PubMed and EMBASE up to September 2015. Studies that reported the detection rate of ICG fluorescence-guided SLNB with full axillary lymph node dissection and histological or immunohistochemical examinations were included. A meta-analysis was performed to generate pooled detection rate, sensitivity, specificity, false negative rate, diagnostic odds ratio (DOR) and a summary receiver operator characteristic curve (SROC).</p><p>Results</p><p>Nineteen published studies were included to generate a pooled detection rate, comprising 2594 patients. The pooled detection rate was 0.98 (95% confidence interval [CI], 0.96–0.99). Six studies finally met the criteria for meta-analysis, which yielded a pooled sensitivity of 0.92 (95% CI, 0.85–0.96), specificity 1 (95% CI, 0.97–1), and DOR 311.47 (95% CI, 84.11–1153.39). The area under the SROC was 0.9758. No publication bias was found.</p><p>Conclusion</p><p>ICG fluorescence-guided SLNB is viable for detection of lymph node metastases in breast cancer. Large-scale randomized multi-center trials are necessary to confirm our results.</p></div

Nineteen studies of the pooled detection rate analysis.

<p>Nineteen studies of the pooled detection rate analysis.</p

Nineteen studies for the pooled detection rate analysis.

<p>Nineteen studies for the pooled detection rate analysis.</p

The pooled DOR was 311.47 (95% CI, 84.11–1153.39).

<p>The pooled DOR was 311.47 (95% CI, 84.11–1153.39).</p

The pooled detection rates was 0.98 (95% confidence interval [CI], 0.96–0.99).

<p>The pooled detection rates was 0.98 (95% confidence interval [CI], 0.96–0.99).</p